Isotechnika granted Norwegian patent for lead immunosuppressive drug

Nov 27 2007

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

Obtaining the patent in Norway completes the protection over the novel structural features of ISA247 in Europe. A total of 83 patents worldwide have been issued relating to ISA247's structure, composition, formulation and methods of synthesis. "In accordance with our overall strategic plan, we continue to secure patent protection worldwide in anticipation of acquiring market approval for ISA247," stated Dr. Robert Foster, Isotechnika's Chairman and Chief Executive Officer. "This indicates that ISA247 will have exclusivity for at least another 15 years. Additional claims for ISA247 will be pursued to ensure that intellectual property is secured in all of the major markets worldwide."

Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential exceeds $2 billion annually in sales for calcineurin inhibitors such as ISA247.

ISA247 is currently being investigated in a Phase 2b North American trial for the prevention of kidney graft rejection subsequent to transplantation and a Phase 3 European/Canadian psoriasis trial.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

• Roche retains an option to continue development of the transplant indications based on the successful completion of the ongoing Phase 2b kidney transplant trial.
• Atrium Medical Corporation has exclusive worldwide licensing agreement for use of ISA247 and TAFA93 with drug eluting devices for non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.
• Lux Biosciences Inc. was granted worldwide rights to develop and commercialize ISA247 for the treatment and prophylaxis of all ophthalmic diseases.